Biotechnology
J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Phase 1/2 IND approved by US FDA
- First patient expected in December 2022 SEOUL, South Korea, Nov. 10, 2022 /PRNewswire/ -- J INTS BIO announced on November 9th that it had received approval from the US FDA for its Phase 1/2 clinical trial of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' in patients with advanced non-small ...
2022-11-11 10:30
2803
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) today announced that Nona Biosciences, a subsidiary wholly owned by the Company, had entered into a license and collaboration agreement with ModernaTX, Inc. (NASDA...
2022-11-11 09:03
3150
Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting
- Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 monoclonal antibody,tracking to an investigational new drug (IND) filing in H1:2023 - Three poster presentations showcase preclinical data with three programs developed or discovered in-house,ATG-1...
2022-11-11 08:30
3304
CBC-backed ABio-X appoints pharmaceutical and healthcare veteran Dr. Jeffrey Jonas as CEO
WALTHAM, Mass., Nov. 10, 2022 /PRNewswire/ -- ABio-X, the Massachusetts-based biotech incubation platform focused on transformative medicines and breakthrough technologies, today announced the appointment ofJeffrey Jonas, M.D., as its Chief Executive Officer (CEO). Dr. Jonas brings with him mo...
2022-11-10 21:00
3313
Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
SHANGHAI, Nov. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) appl...
2022-11-10 19:02
2390
Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual c-Myc/GSPT1 Degrader GT19715
SUZHOU, China, Nov. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("KintorPharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the results from the novel dual c-Myc/GSPT1 degrader GT19715 have been s...
2022-11-10 09:12
2801
ScoliCare Opens its First Clinic in the US
New service will treat scoliosis and hyperkyphosis patients in Florida NAPLES, Fla. , Nov. 8, 2022 /PRNewswire/ -- ScoliCare, Australia's largest provider of non-surgical scoliosis and hyperkyphosis treatment and leading worldwide brace manufacturer (ScoliBrace®), today announced the opening of i...
2022-11-08 23:27
3007
Traditional Chinese Medicine Lianhua Qingwen Attracted Eyes in the Annual National Conference of Pharmaceutical Society of Nigeria
SHIJIAZHUANG, China, Nov. 8, 2022 /PRNewswire/ -- Recently, the 95th National Annual Conference of the Pharmaceutical Society ofNigeria was held in Jos, capital of Plateau State. The theme of the Conference in this year was "Medicine Security in an Unstable Economy", and more than 3,000 doctors a...
2022-11-08 20:25
2556
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO, Nov. 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation fro...
2022-11-07 23:25
3279
Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research--Findings to be Presented at SITC 2022
* Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development. SEOUL, South Korea, Nov. 7, ...
2022-11-07 21:00
2766
Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting
- Poster with updated Phase Ib TOUCH results suggest selinexor plus GemOx could provide a therapeutic option for heavily pre-treated Stage III/IV patients with relapsed/refractory (R/R) T and NK-cell lymphoma - Online abstract with results from the open-label LAUNCH study demonstrated the encoura...
2022-11-07 14:38
2330
Certa Therapeutics' investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
* Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data * The research demonstrated that treatment with FT011 results in a remarkable...
2022-11-04 20:00
3080
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharm...
2022-11-03 21:10
2769
Yuyu Pharma attendance at European Pharmaceutical Conference
SEOUL, South Korea, Nov. 3, 2022 /PRNewswire/ -- Robert Yu, CEO of Yuyu Pharma,
has been attending biopharmaceutical conferences held inGermany, BIO-Europe and
CPHI. The purpose is to explore opportunities to expand into international
markets, such as Europe.
2022-11-03 21:00
3683
Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation
The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization ...
2022-11-03 19:00
2087
I Peace partners with the California Institute for Regenerative Medicine [CIRM]
PALO ALTO, Calif., Nov. 1, 2022 /PRNewswire/ -- I Peace, Inc. (
https://www.ipeace.com
2022-11-02 00:00
2705
Real-World Application of Lunit INSIGHT to be Spotlighted at RSNA 2022 (Oral Presentations)
* 7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI solution for radiology, have been accepted by RSNA * Program will include studies evaluating the performance of Lunit's commercial AI software across massive real-world population groups * Software ...
2022-11-01 22:00
3095
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs
SHANGHAI, Oct. 31, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Sylvie Peltier ("Dr. Peltier") has been appointed as Senior V...
2022-10-31 21:30
3407
Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 31, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2022-10-31 21:00
2949
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022
HONG KONG, Oct. 30, 2022 /PRNewswire/ -- Akeso, Biopharma (9926. HK) ("Akeso") released the Phase Ib clinical results of Ivonescimab (PD-1/VEGF bi-specific, AK112) in combination with etoposide and carboplatin in first-line treatment of extensive-stage small-cell lung cancer(ES-SCLC), in an oral ...
2022-10-31 08:40
2324
Week's Top Stories
Most Reposted
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 299 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 292 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 292 media titles]
2026-06-05 15:00FPT and NVIDIA Collaborate to Release the Nemotron Personas Vietnam Datasets
[Picked up by 276 media titles]
2026-06-05 17:34
Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Most Read
WePlay Korea's 4th Anniversary Celebration Kicks Off, Joining Hands with "Hello Panda-哈啰潘达" to Create Fu Bao Themed Space Decorations
2026-06-01 12:00
7717
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)
2026-06-05 21:05
7137
CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS
2026-06-05 20:58
6782
NYSE Content Update: FedEx Freight to List on the NYSE + Join S&P 500
2026-06-01 21:32
6371
